SlideShare a Scribd company logo
1 of 14
Triage of cases-with seriousness
and expectedness
Name – Sumit
Roll no. 2250981548
Triaging
Triage is the assessment, classification & prioritization of the
information received according to key regulatory, scientific
and medical criteria.
Triage
Seriousness
Relatedness
Expectedness
SERIOUSNESS ASSESSMENT
 Seriousness of an ADR is related to its life threatening
nature and is defined as any untoward reaction to the
medicinal product that may result in death and requires
patient hospitalization.
 Seriousness of reaction is categorized according to FDA
criteria on the basis of their life threatening nature.
1. Death.
2. Life-threatening.
3. Hospitalization (initial or prolonged).
4. Disability or Permanent Damage.
5. Congenital Anomaly/Birth Defect.
6. Medical Significant.
1. Death
1. Death should be considered as seriousness criteria only if
it is reported by reporter.
2. The reporter must mention in the report that patient died
while on/after receiving treatment medication.
3. If reported event is completed suicide then it should be
categorised under death.
4. If reported event is suicide then follow up request to be
sent to confirm as attempted suicide or completed suicide.
For example: A patient experienced an ADR after the
administration of Drug A and died in an airplane accident.
2. Life-threatening
1. Life-threatening refers to a reaction in which the patient
was at risk of death at the time of the reaction; It does not
refer to a reaction that hypothetically might have caused
death if more severe.
2. For example, if patient had cardiac arrest and taken to
hospital then seriousness willbe hospitalisation not life
threatening.
3. If patient was in coma or require ventilator support can be
considered as lifE threatening conditions.
4. Life threatening can be considered as seriousness if
reporter clearly mentions inreport that patient is in Life
threatening condition.
3. Hospitalization:
 Hospitalisation considered as serious criteria if patient
administered to hospital (with minimum 24 hrs stay) or
caused prolongation of hospitalisation for any event.
 Example:
 Patient was admitted to emergency department due to
severe headache experienced after administration of Drug
A.
 Patient was admitted to emergency department due to
diabetic foot and was put on Drug A. On the day of
discharge, she experienced severe gastritis, vomiting and
abdominal pain. Patient was treated with Drug B ad
discharged after 2 days.
4. Disability/incapacity:
 A substantial disruption of a person’s ability to conduct
normal life function.’’ (FDA definition)
 Applicable when and ADR resulted in alteration of function
or of quality of life for a particular duration •
 For example: –
 Headache lasting 24 hours
 Partial deafness in one ear
5. Congenital anomaly/birth defect:
1. Congenital anomalies, also commonly referred to as birth
defects, congenital disorders, congenital malformations,
or congenital abnormalities, are conditions of prenatal
origin that are present at birth, potentially impacting an
infant's health, development and/or survival.
2. This seriousness criteria can be used only in pregnancy
reports where parent exposed to medication while mother
being pregnant and baby had birth defect
because of medication.
6. Medically Important/Significant:
 Medical judgment shall be exercised to define the
seriousness of the case-based type of adverse event and
intervention required to treat the adverse event. •
 These cases will be considered as serious.
 Under EU Pharmacovigilance system, an important medical
event (IME) terms list is available based on the Medical
Dictionary for Regulatory Activities (MedDRA) Preferred
terms. The IME list is referred to define seriousness of case
based on Medically Important/Significant.
 In safety database, the IME list is integrated to assign the
seriousness automatically once the particular adverse event
is populated.
EXPECTEDNESS DETERMINATION
 Very important part of case processing to determine
expectedness of adverse event reported in the relevant
Reference safety information documents of the medicinal
product.
 A signs, symptoms or diagnosis reported in a case which
are present in the list (even as synonyms) of adverse
reactions in an RSI document will be classified as
‘‘Expected’’.
 A signs, symptoms or diagnosis reported in a case which
are different or present with different severity (mild,
moderate, severe) in adverse reactions list of RSI will be
classified as ‘‘Unexpected’’.
 RSI may be one or more of the following:
Investigator Brochure (IB)
Company’s core safety information (CCSI) within its
internal core data sheet, or
The official local data sheet (e.g., Package Insert in the
US, Summary of Product Characteristics (SPC) in the
EU).
 The terms Listed/Unlisted will be used for ADRs referred
in IB/CCSI
 The terms Labeled/Unlabeled will be used for ADRs
referred in PI/SmPC.
 The terms 'Listed/Labelled” are used during assessment for
the “Marketed products”.
 The term “Expectedness” is used during assessment for
“Developmental drugs or Investigational molecules.
POINTS TO CONSIDER:
 Medical judgments shall be made in regards to choice of
term and clinical evidence of the term to assess the
expectedness.
 If ‘‘verbatim’’ term of ADR reported is not present in the
RSI, synonym or medically equivalent term should be
identified and consider for expectedness.
 If ADR presented in the RSI in overdose section then same
ADR if reported with normal dose of the drug should be
considered as “Unexpected”.
 Expectedness should be determine for drug associated
medical experiences only like any adverse event happened
before the drug administrations should not be considered
for expectedness assessment.
 In addition to Adverse Event list of RSI document, other
sections clinical pharmacology, contraindications,
warnings, precautions should also be included for
expectedness assessment.
 Death Cases: In situations where ADR is associated with
death as outcome, the case should be considered
‘Unexpected’ until unless the RSI specify a fatal outcome
associated with ADR.
 TRIAGE Categories
Serious + Unexpected
Serious + Expected
Non-serious + Unexpected
Non-serious + Expected
triage ppt.pptx

More Related Content

What's hot

Aggregate Reporting_Pharmacovigilance_Katalyst HLS
Aggregate Reporting_Pharmacovigilance_Katalyst HLSAggregate Reporting_Pharmacovigilance_Katalyst HLS
Aggregate Reporting_Pharmacovigilance_Katalyst HLSKatalyst HLS
 
An Introduction to the Pharmacovigilance System Master File
An Introduction to the Pharmacovigilance System Master FileAn Introduction to the Pharmacovigilance System Master File
An Introduction to the Pharmacovigilance System Master FileTransPerfect Trial Interactive
 
Literature monitoring for pharmacovigilance – outsourcing or in house solution
Literature monitoring for pharmacovigilance – outsourcing or in house solutionLiterature monitoring for pharmacovigilance – outsourcing or in house solution
Literature monitoring for pharmacovigilance – outsourcing or in house solutionJulio dos Anjos
 
Volume 9 A Guidelines On Pharmacovigilance[1]
Volume 9 A Guidelines On Pharmacovigilance[1]Volume 9 A Guidelines On Pharmacovigilance[1]
Volume 9 A Guidelines On Pharmacovigilance[1]siddharthchachad
 
Pharma regulatory affairs
Pharma regulatory affairsPharma regulatory affairs
Pharma regulatory affairsGirish Swami
 
Presentation: Periodic safety update reports
Presentation: Periodic safety update reportsPresentation: Periodic safety update reports
Presentation: Periodic safety update reportsTGA Australia
 
Good Clinical Practice and Pharmacovigilance
Good Clinical Practice and PharmacovigilanceGood Clinical Practice and Pharmacovigilance
Good Clinical Practice and PharmacovigilanceMd. Zakaria Faruki
 
Methods of Pharmacovigilance.pptx
Methods of Pharmacovigilance.pptxMethods of Pharmacovigilance.pptx
Methods of Pharmacovigilance.pptxPraveen kumar S
 
7.Safety Monitoring in Clinical Trails.pptx
7.Safety Monitoring in Clinical Trails.pptx7.Safety Monitoring in Clinical Trails.pptx
7.Safety Monitoring in Clinical Trails.pptxbrahmaiahmph
 
Types of pharmacovigilance softwares
Types of pharmacovigilance softwaresTypes of pharmacovigilance softwares
Types of pharmacovigilance softwaresSollers College
 
Regulatory aspects of orphan drugs devolpments
Regulatory aspects of orphan drugs devolpmentsRegulatory aspects of orphan drugs devolpments
Regulatory aspects of orphan drugs devolpmentsJITHIN K JOY
 
Pharmacovigilance sytem in United States of America (USA)
Pharmacovigilance sytem in United States of America (USA)Pharmacovigilance sytem in United States of America (USA)
Pharmacovigilance sytem in United States of America (USA)PharmXL International Pvt. Ltd.
 
Pharmacovigilance (pv)
Pharmacovigilance (pv)Pharmacovigilance (pv)
Pharmacovigilance (pv)Reena Titoria
 
IND and CTA Webinar slides.pptx
IND and CTA Webinar slides.pptxIND and CTA Webinar slides.pptx
IND and CTA Webinar slides.pptxMMS Holdings
 

What's hot (20)

Aggregate Reporting_Pharmacovigilance_Katalyst HLS
Aggregate Reporting_Pharmacovigilance_Katalyst HLSAggregate Reporting_Pharmacovigilance_Katalyst HLS
Aggregate Reporting_Pharmacovigilance_Katalyst HLS
 
An Introduction to the Pharmacovigilance System Master File
An Introduction to the Pharmacovigilance System Master FileAn Introduction to the Pharmacovigilance System Master File
An Introduction to the Pharmacovigilance System Master File
 
DSUR
DSURDSUR
DSUR
 
Literature monitoring for pharmacovigilance – outsourcing or in house solution
Literature monitoring for pharmacovigilance – outsourcing or in house solutionLiterature monitoring for pharmacovigilance – outsourcing or in house solution
Literature monitoring for pharmacovigilance – outsourcing or in house solution
 
Volume 9 A Guidelines On Pharmacovigilance[1]
Volume 9 A Guidelines On Pharmacovigilance[1]Volume 9 A Guidelines On Pharmacovigilance[1]
Volume 9 A Guidelines On Pharmacovigilance[1]
 
Pharma regulatory affairs
Pharma regulatory affairsPharma regulatory affairs
Pharma regulatory affairs
 
Hash 3-1.pptx
Hash 3-1.pptxHash 3-1.pptx
Hash 3-1.pptx
 
Presentation: Periodic safety update reports
Presentation: Periodic safety update reportsPresentation: Periodic safety update reports
Presentation: Periodic safety update reports
 
Good Clinical Practice and Pharmacovigilance
Good Clinical Practice and PharmacovigilanceGood Clinical Practice and Pharmacovigilance
Good Clinical Practice and Pharmacovigilance
 
PV methods.pptx
PV methods.pptxPV methods.pptx
PV methods.pptx
 
Methods of Pharmacovigilance.pptx
Methods of Pharmacovigilance.pptxMethods of Pharmacovigilance.pptx
Methods of Pharmacovigilance.pptx
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
 
7.Safety Monitoring in Clinical Trails.pptx
7.Safety Monitoring in Clinical Trails.pptx7.Safety Monitoring in Clinical Trails.pptx
7.Safety Monitoring in Clinical Trails.pptx
 
Med dra Basics
Med dra  BasicsMed dra  Basics
Med dra Basics
 
Types of pharmacovigilance softwares
Types of pharmacovigilance softwaresTypes of pharmacovigilance softwares
Types of pharmacovigilance softwares
 
Regulatory aspects of orphan drugs devolpments
Regulatory aspects of orphan drugs devolpmentsRegulatory aspects of orphan drugs devolpments
Regulatory aspects of orphan drugs devolpments
 
Pharmacovigilance sytem in United States of America (USA)
Pharmacovigilance sytem in United States of America (USA)Pharmacovigilance sytem in United States of America (USA)
Pharmacovigilance sytem in United States of America (USA)
 
ICH - E2D Pharmacovigilance and Drug Safety - Professor Peivand Pirouzi
ICH - E2D Pharmacovigilance and Drug Safety - Professor Peivand PirouziICH - E2D Pharmacovigilance and Drug Safety - Professor Peivand Pirouzi
ICH - E2D Pharmacovigilance and Drug Safety - Professor Peivand Pirouzi
 
Pharmacovigilance (pv)
Pharmacovigilance (pv)Pharmacovigilance (pv)
Pharmacovigilance (pv)
 
IND and CTA Webinar slides.pptx
IND and CTA Webinar slides.pptxIND and CTA Webinar slides.pptx
IND and CTA Webinar slides.pptx
 

Similar to triage ppt.pptx

Pharmacovigilance overview shraddha
Pharmacovigilance  overview shraddhaPharmacovigilance  overview shraddha
Pharmacovigilance overview shraddhaDr. Shraddha Bhange
 
How to recognize ADRs in patients.@ Clinical Pharmacy
How to recognize ADRs in patients.@ Clinical PharmacyHow to recognize ADRs in patients.@ Clinical Pharmacy
How to recognize ADRs in patients.@ Clinical PharmacyDrpradeepthi
 
Detecting Reporting ADR.pptx
Detecting  Reporting ADR.pptxDetecting  Reporting ADR.pptx
Detecting Reporting ADR.pptxAjithJs2
 
Regulatory terminology of ADR and Establishing pharmacovigilance center's i...
Regulatory terminology of ADR  and  Establishing pharmacovigilance center's i...Regulatory terminology of ADR  and  Establishing pharmacovigilance center's i...
Regulatory terminology of ADR and Establishing pharmacovigilance center's i...SIRAJUDDIN MOLLA
 
ICSR Workflow & Management_Katalyst HLS
ICSR Workflow & Management_Katalyst HLSICSR Workflow & Management_Katalyst HLS
ICSR Workflow & Management_Katalyst HLSKatalyst HLS
 
Pharmacovigilance by khaga
Pharmacovigilance by khagaPharmacovigilance by khaga
Pharmacovigilance by khagaKhadga Raj
 
Guidelines on adr reporting
Guidelines on adr reportingGuidelines on adr reporting
Guidelines on adr reportingSaiLakshmi110
 
1591115199267_Pharmacovigilance.pptx
1591115199267_Pharmacovigilance.pptx1591115199267_Pharmacovigilance.pptx
1591115199267_Pharmacovigilance.pptxDrAniqaSundas
 
Adverse Event Reporting in Pharmacovigilance: Principles and Challenges
Adverse Event Reporting in Pharmacovigilance: Principles and ChallengesAdverse Event Reporting in Pharmacovigilance: Principles and Challenges
Adverse Event Reporting in Pharmacovigilance: Principles and ChallengesClinosolIndia
 
Pharmacovigilance overview
Pharmacovigilance overviewPharmacovigilance overview
Pharmacovigilance overviewAcri India
 
Safety_Data_Reconciliation_Katalyst HLS
Safety_Data_Reconciliation_Katalyst HLSSafety_Data_Reconciliation_Katalyst HLS
Safety_Data_Reconciliation_Katalyst HLSKatalyst HLS
 
Safety Considerations Regulatory Definitions and Practical Considerations Ram...
Safety Considerations Regulatory Definitions and Practical Considerations Ram...Safety Considerations Regulatory Definitions and Practical Considerations Ram...
Safety Considerations Regulatory Definitions and Practical Considerations Ram...yerroju vijay
 
Post marketing surveillance
Post marketing surveillancePost marketing surveillance
Post marketing surveillanceDr. Vijesha Soni
 

Similar to triage ppt.pptx (20)

Pharmacovigilance overview shraddha
Pharmacovigilance  overview shraddhaPharmacovigilance  overview shraddha
Pharmacovigilance overview shraddha
 
How to recognize ADRs in patients.@ Clinical Pharmacy
How to recognize ADRs in patients.@ Clinical PharmacyHow to recognize ADRs in patients.@ Clinical Pharmacy
How to recognize ADRs in patients.@ Clinical Pharmacy
 
Detecting Reporting ADR.pptx
Detecting  Reporting ADR.pptxDetecting  Reporting ADR.pptx
Detecting Reporting ADR.pptx
 
Pharmacovigilance pdf
Pharmacovigilance pdfPharmacovigilance pdf
Pharmacovigilance pdf
 
Pharmacovigilance suresh
Pharmacovigilance  sureshPharmacovigilance  suresh
Pharmacovigilance suresh
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
 
Regulatory terminology of ADR and Establishing pharmacovigilance center's i...
Regulatory terminology of ADR  and  Establishing pharmacovigilance center's i...Regulatory terminology of ADR  and  Establishing pharmacovigilance center's i...
Regulatory terminology of ADR and Establishing pharmacovigilance center's i...
 
Adverse drug reactions
Adverse drug reactionsAdverse drug reactions
Adverse drug reactions
 
ICSR Workflow & Management_Katalyst HLS
ICSR Workflow & Management_Katalyst HLSICSR Workflow & Management_Katalyst HLS
ICSR Workflow & Management_Katalyst HLS
 
Pharmacovigilance by khaga
Pharmacovigilance by khagaPharmacovigilance by khaga
Pharmacovigilance by khaga
 
Guidelines on adr reporting
Guidelines on adr reportingGuidelines on adr reporting
Guidelines on adr reporting
 
1591115199267_Pharmacovigilance.pptx
1591115199267_Pharmacovigilance.pptx1591115199267_Pharmacovigilance.pptx
1591115199267_Pharmacovigilance.pptx
 
Vaishali chadha
Vaishali chadhaVaishali chadha
Vaishali chadha
 
Pv
PvPv
Pv
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
 
Adverse Event Reporting in Pharmacovigilance: Principles and Challenges
Adverse Event Reporting in Pharmacovigilance: Principles and ChallengesAdverse Event Reporting in Pharmacovigilance: Principles and Challenges
Adverse Event Reporting in Pharmacovigilance: Principles and Challenges
 
Pharmacovigilance overview
Pharmacovigilance overviewPharmacovigilance overview
Pharmacovigilance overview
 
Safety_Data_Reconciliation_Katalyst HLS
Safety_Data_Reconciliation_Katalyst HLSSafety_Data_Reconciliation_Katalyst HLS
Safety_Data_Reconciliation_Katalyst HLS
 
Safety Considerations Regulatory Definitions and Practical Considerations Ram...
Safety Considerations Regulatory Definitions and Practical Considerations Ram...Safety Considerations Regulatory Definitions and Practical Considerations Ram...
Safety Considerations Regulatory Definitions and Practical Considerations Ram...
 
Post marketing surveillance
Post marketing surveillancePost marketing surveillance
Post marketing surveillance
 

More from VermaG3

Managerial Skills 4.pptx
Managerial Skills 4.pptxManagerial Skills 4.pptx
Managerial Skills 4.pptxVermaG3
 
Professional-Etiquette-3.pptx
Professional-Etiquette-3.pptxProfessional-Etiquette-3.pptx
Professional-Etiquette-3.pptxVermaG3
 
PROJECT MANGEMENT.pptx
PROJECT MANGEMENT.pptxPROJECT MANGEMENT.pptx
PROJECT MANGEMENT.pptxVermaG3
 
Leadership_Group 1.pptx
Leadership_Group 1.pptxLeadership_Group 1.pptx
Leadership_Group 1.pptxVermaG3
 
assinment signal.pptx
assinment signal.pptxassinment signal.pptx
assinment signal.pptxVermaG3
 
medDRA SMQ TOPIC.pptx
medDRA SMQ TOPIC.pptxmedDRA SMQ TOPIC.pptx
medDRA SMQ TOPIC.pptxVermaG3
 
EPILEPSY.pptx
EPILEPSY.pptxEPILEPSY.pptx
EPILEPSY.pptxVermaG3
 

More from VermaG3 (7)

Managerial Skills 4.pptx
Managerial Skills 4.pptxManagerial Skills 4.pptx
Managerial Skills 4.pptx
 
Professional-Etiquette-3.pptx
Professional-Etiquette-3.pptxProfessional-Etiquette-3.pptx
Professional-Etiquette-3.pptx
 
PROJECT MANGEMENT.pptx
PROJECT MANGEMENT.pptxPROJECT MANGEMENT.pptx
PROJECT MANGEMENT.pptx
 
Leadership_Group 1.pptx
Leadership_Group 1.pptxLeadership_Group 1.pptx
Leadership_Group 1.pptx
 
assinment signal.pptx
assinment signal.pptxassinment signal.pptx
assinment signal.pptx
 
medDRA SMQ TOPIC.pptx
medDRA SMQ TOPIC.pptxmedDRA SMQ TOPIC.pptx
medDRA SMQ TOPIC.pptx
 
EPILEPSY.pptx
EPILEPSY.pptxEPILEPSY.pptx
EPILEPSY.pptx
 

Recently uploaded

CARE OF CHILD IN INCUBATOR..........pptx
CARE OF CHILD IN INCUBATOR..........pptxCARE OF CHILD IN INCUBATOR..........pptx
CARE OF CHILD IN INCUBATOR..........pptxGaneshChakor2
 
Advanced Views - Calendar View in Odoo 17
Advanced Views - Calendar View in Odoo 17Advanced Views - Calendar View in Odoo 17
Advanced Views - Calendar View in Odoo 17Celine George
 
1029 - Danh muc Sach Giao Khoa 10 . pdf
1029 -  Danh muc Sach Giao Khoa 10 . pdf1029 -  Danh muc Sach Giao Khoa 10 . pdf
1029 - Danh muc Sach Giao Khoa 10 . pdfQucHHunhnh
 
Employee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptxEmployee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptxNirmalaLoungPoorunde1
 
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdfssuser54595a
 
Beyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global ImpactBeyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global ImpactPECB
 
Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...
Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...
Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...Krashi Coaching
 
Hybridoma Technology ( Production , Purification , and Application )
Hybridoma Technology  ( Production , Purification , and Application  ) Hybridoma Technology  ( Production , Purification , and Application  )
Hybridoma Technology ( Production , Purification , and Application ) Sakshi Ghasle
 
Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104misteraugie
 
Organic Name Reactions for the students and aspirants of Chemistry12th.pptx
Organic Name Reactions  for the students and aspirants of Chemistry12th.pptxOrganic Name Reactions  for the students and aspirants of Chemistry12th.pptx
Organic Name Reactions for the students and aspirants of Chemistry12th.pptxVS Mahajan Coaching Centre
 
Mastering the Unannounced Regulatory Inspection
Mastering the Unannounced Regulatory InspectionMastering the Unannounced Regulatory Inspection
Mastering the Unannounced Regulatory InspectionSafetyChain Software
 
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...Marc Dusseiller Dusjagr
 
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptxPOINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptxSayali Powar
 
microwave assisted reaction. General introduction
microwave assisted reaction. General introductionmicrowave assisted reaction. General introduction
microwave assisted reaction. General introductionMaksud Ahmed
 
Grant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy ConsultingGrant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy ConsultingTechSoup
 
mini mental status format.docx
mini    mental       status     format.docxmini    mental       status     format.docx
mini mental status format.docxPoojaSen20
 
Activity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfActivity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfciinovamais
 
The basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptxThe basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptxheathfieldcps1
 
Software Engineering Methodologies (overview)
Software Engineering Methodologies (overview)Software Engineering Methodologies (overview)
Software Engineering Methodologies (overview)eniolaolutunde
 
Introduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptxIntroduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptxpboyjonauth
 

Recently uploaded (20)

CARE OF CHILD IN INCUBATOR..........pptx
CARE OF CHILD IN INCUBATOR..........pptxCARE OF CHILD IN INCUBATOR..........pptx
CARE OF CHILD IN INCUBATOR..........pptx
 
Advanced Views - Calendar View in Odoo 17
Advanced Views - Calendar View in Odoo 17Advanced Views - Calendar View in Odoo 17
Advanced Views - Calendar View in Odoo 17
 
1029 - Danh muc Sach Giao Khoa 10 . pdf
1029 -  Danh muc Sach Giao Khoa 10 . pdf1029 -  Danh muc Sach Giao Khoa 10 . pdf
1029 - Danh muc Sach Giao Khoa 10 . pdf
 
Employee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptxEmployee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptx
 
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
 
Beyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global ImpactBeyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global Impact
 
Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...
Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...
Kisan Call Centre - To harness potential of ICT in Agriculture by answer farm...
 
Hybridoma Technology ( Production , Purification , and Application )
Hybridoma Technology  ( Production , Purification , and Application  ) Hybridoma Technology  ( Production , Purification , and Application  )
Hybridoma Technology ( Production , Purification , and Application )
 
Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104
 
Organic Name Reactions for the students and aspirants of Chemistry12th.pptx
Organic Name Reactions  for the students and aspirants of Chemistry12th.pptxOrganic Name Reactions  for the students and aspirants of Chemistry12th.pptx
Organic Name Reactions for the students and aspirants of Chemistry12th.pptx
 
Mastering the Unannounced Regulatory Inspection
Mastering the Unannounced Regulatory InspectionMastering the Unannounced Regulatory Inspection
Mastering the Unannounced Regulatory Inspection
 
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
 
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptxPOINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
 
microwave assisted reaction. General introduction
microwave assisted reaction. General introductionmicrowave assisted reaction. General introduction
microwave assisted reaction. General introduction
 
Grant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy ConsultingGrant Readiness 101 TechSoup and Remy Consulting
Grant Readiness 101 TechSoup and Remy Consulting
 
mini mental status format.docx
mini    mental       status     format.docxmini    mental       status     format.docx
mini mental status format.docx
 
Activity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfActivity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdf
 
The basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptxThe basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptx
 
Software Engineering Methodologies (overview)
Software Engineering Methodologies (overview)Software Engineering Methodologies (overview)
Software Engineering Methodologies (overview)
 
Introduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptxIntroduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptx
 

triage ppt.pptx

  • 1. Triage of cases-with seriousness and expectedness Name – Sumit Roll no. 2250981548
  • 2. Triaging Triage is the assessment, classification & prioritization of the information received according to key regulatory, scientific and medical criteria. Triage Seriousness Relatedness Expectedness
  • 3. SERIOUSNESS ASSESSMENT  Seriousness of an ADR is related to its life threatening nature and is defined as any untoward reaction to the medicinal product that may result in death and requires patient hospitalization.  Seriousness of reaction is categorized according to FDA criteria on the basis of their life threatening nature. 1. Death. 2. Life-threatening. 3. Hospitalization (initial or prolonged). 4. Disability or Permanent Damage. 5. Congenital Anomaly/Birth Defect. 6. Medical Significant.
  • 4. 1. Death 1. Death should be considered as seriousness criteria only if it is reported by reporter. 2. The reporter must mention in the report that patient died while on/after receiving treatment medication. 3. If reported event is completed suicide then it should be categorised under death. 4. If reported event is suicide then follow up request to be sent to confirm as attempted suicide or completed suicide. For example: A patient experienced an ADR after the administration of Drug A and died in an airplane accident.
  • 5. 2. Life-threatening 1. Life-threatening refers to a reaction in which the patient was at risk of death at the time of the reaction; It does not refer to a reaction that hypothetically might have caused death if more severe. 2. For example, if patient had cardiac arrest and taken to hospital then seriousness willbe hospitalisation not life threatening. 3. If patient was in coma or require ventilator support can be considered as lifE threatening conditions. 4. Life threatening can be considered as seriousness if reporter clearly mentions inreport that patient is in Life threatening condition.
  • 6. 3. Hospitalization:  Hospitalisation considered as serious criteria if patient administered to hospital (with minimum 24 hrs stay) or caused prolongation of hospitalisation for any event.  Example:  Patient was admitted to emergency department due to severe headache experienced after administration of Drug A.  Patient was admitted to emergency department due to diabetic foot and was put on Drug A. On the day of discharge, she experienced severe gastritis, vomiting and abdominal pain. Patient was treated with Drug B ad discharged after 2 days.
  • 7. 4. Disability/incapacity:  A substantial disruption of a person’s ability to conduct normal life function.’’ (FDA definition)  Applicable when and ADR resulted in alteration of function or of quality of life for a particular duration •  For example: –  Headache lasting 24 hours  Partial deafness in one ear
  • 8. 5. Congenital anomaly/birth defect: 1. Congenital anomalies, also commonly referred to as birth defects, congenital disorders, congenital malformations, or congenital abnormalities, are conditions of prenatal origin that are present at birth, potentially impacting an infant's health, development and/or survival. 2. This seriousness criteria can be used only in pregnancy reports where parent exposed to medication while mother being pregnant and baby had birth defect because of medication.
  • 9. 6. Medically Important/Significant:  Medical judgment shall be exercised to define the seriousness of the case-based type of adverse event and intervention required to treat the adverse event. •  These cases will be considered as serious.  Under EU Pharmacovigilance system, an important medical event (IME) terms list is available based on the Medical Dictionary for Regulatory Activities (MedDRA) Preferred terms. The IME list is referred to define seriousness of case based on Medically Important/Significant.  In safety database, the IME list is integrated to assign the seriousness automatically once the particular adverse event is populated.
  • 10. EXPECTEDNESS DETERMINATION  Very important part of case processing to determine expectedness of adverse event reported in the relevant Reference safety information documents of the medicinal product.  A signs, symptoms or diagnosis reported in a case which are present in the list (even as synonyms) of adverse reactions in an RSI document will be classified as ‘‘Expected’’.  A signs, symptoms or diagnosis reported in a case which are different or present with different severity (mild, moderate, severe) in adverse reactions list of RSI will be classified as ‘‘Unexpected’’.
  • 11.  RSI may be one or more of the following: Investigator Brochure (IB) Company’s core safety information (CCSI) within its internal core data sheet, or The official local data sheet (e.g., Package Insert in the US, Summary of Product Characteristics (SPC) in the EU).  The terms Listed/Unlisted will be used for ADRs referred in IB/CCSI  The terms Labeled/Unlabeled will be used for ADRs referred in PI/SmPC.  The terms 'Listed/Labelled” are used during assessment for the “Marketed products”.  The term “Expectedness” is used during assessment for “Developmental drugs or Investigational molecules.
  • 12. POINTS TO CONSIDER:  Medical judgments shall be made in regards to choice of term and clinical evidence of the term to assess the expectedness.  If ‘‘verbatim’’ term of ADR reported is not present in the RSI, synonym or medically equivalent term should be identified and consider for expectedness.  If ADR presented in the RSI in overdose section then same ADR if reported with normal dose of the drug should be considered as “Unexpected”.  Expectedness should be determine for drug associated medical experiences only like any adverse event happened before the drug administrations should not be considered for expectedness assessment.
  • 13.  In addition to Adverse Event list of RSI document, other sections clinical pharmacology, contraindications, warnings, precautions should also be included for expectedness assessment.  Death Cases: In situations where ADR is associated with death as outcome, the case should be considered ‘Unexpected’ until unless the RSI specify a fatal outcome associated with ADR.  TRIAGE Categories Serious + Unexpected Serious + Expected Non-serious + Unexpected Non-serious + Expected